On August 13, 2014, Novartis AG filed a lawsuit against Breckenridge in the United States District Court for the District of Delaware. Breckenridge submitted its Paragraph IV ANDA
Specifically, results from this study of 20 healthy adults demonstrated that the mean time to peak plasma concentration following administration of a single 900mg dose of delafloxacin was
SGX301 is poised to enter pivotal Phase 3 clinical testing for the treatment of cutaneous T-cell lymphoma (CTCL) and is highly synergistic with the company’s existing development pipeline.
As agreed with FDA, ceftazidime-avibactam was submitted as a 505(b)(2) NDA for the treatment of patients with cIAI and cUTI based on the efficacy and safety of ceftazidime,
The addition of BONINE provides significant scale to its U.S.OTC nausea franchise. Its EMETROL brand is the #1 pharmacist recommended nausea remedy, and has provided consumers with relief
The University and biOasis continue to develop biOasis’ extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier
A therapeutically aligned infectious diseases team will support all ID studies at PSI, focused to provide optimized approaches to patient enrollment. The team will include staff from various
The acquisition reflects the organization’s recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space. The real estate
The results of this Phase 2 study, investigating the efficacy and safety of this topical ACT1 formulation when combined with standard care in treatment of chronic venous leg
Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product. "There is a significant unmet medical need
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.